Placeholder

LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

TRV51

TRV51 is a preclinical-stage therapeutics company working to development new, small-molecule drugs to transform the lives of patients who have cancers and other life-threatening diseases.

TRV51 logo
Website - Coming Soon
  • Sandra Glucksmann, PhD President and CEO
  • Anna Schinzel, PhD Senior Scientist, Biology